Episode 91: Could Moderna’s mRNA breakthrough transform cancer treatment?

A record share price surge put Moderna back in the headlines, but the bigger story may be what it signals for the future of medicine. Milford Investment Analyst Dr Deborah Lambie joins Ryan Bridge to discuss the breakthrough personalised cancer treatment developed by Moderna and Merck, how mRNA technology is moving beyond Covid-19 vaccines, and why investors believe this could be one of the most significant healthcare developments in years. They also explore the opportunities, risks and commercial realities behind the excitement.

This podcast is intended to provide general information only. It does not take into account your investment needs or personal circumstances. It is not intended to be viewed as investment or financial advice. Should you require financial advice you should always speak to a Financial Adviser. Past performance is not a reliable indicator of future performance. Milford is an active fund manager with views and portfolio positions subject to change. Milford Funds Limited is the issuer of the Milford KiwiSaver Plan and the Milford Investment Funds. Please read the relevant Milford Product Disclosure Statement at milfordasset.com. Before investing, you may wish to seek financial advice. The disclosure statements of all Milford Financial Advisers contain more information and are available for free on request. For more information and to see our Financial Advice Provider Disclosure statement, please visit milfordasset.com/getting-advice